
-
Immunic NasdaqGS:IMUX Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Location: 1200 Avenue of the Americas, New York, NY, 10036, United States | Website: https://imux.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
55.1M
Cash
35.67M
Avg Qtr Burn
-21.19M
Short % of Float
4.24%
Insider Ownership
0.99%
Institutional Own.
44.84%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Vidofludimus calcium (IMU-838) Details Multiple sclerosis, Autoimmune disease | Phase 3 Data readout | |
Vidofludimus calcium (IMU-838) Details Bowel disorder, Inflammatory bowel disease, Ulcerative colitis | Phase 2b Update | |
Vidofludimus calcium (IMU-838) Details COVID-19, Infectious disease | Phase 2 Update | |
Vidofludimus calcium (IMU-838) Details Multiple sclerosis, Autoimmune disease | Phase 2 Update | |
IMU-856 Details Celiac disease | Phase 2 Initiation | |
Izumerogant (IMU-935) Details Psoriasis | Failed Discontinued | |
Vidofludimus calcium (IMU-838) Details Primary sclerosing cholangitis, Bile duct disease, Liver disease | Failed Discontinued |